Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer [ID6477]

  • In development
  • GID-TA11599
  • Expected publication date: 

28856-Pembrolizumab-for-Head-and-Neck-Squamous-Cell-Carcinoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)